Sarepta critic Jenkins is exiting the FDA, and Woodcock takes direct charge of the OND after a painful rupture
A few weeks ago, John Jenkins, the longtime director of the FDA’s Office of New Drugs, caused quite a stir with some advice for biotechs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
